Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937356 | 1.00 | TSHR (0.56) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL1505987 | 1.00 | TSHR (0.56) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL46155 | 0.86 | TSHR (0.72) | TSHR | |
| SCHEMBL16422345 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21353917 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21363715 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21353919 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21393372 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL16423075 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL16422344 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220025424-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES | IMAGO BIOSCIENCES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220025424-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES | IMAGO BIOSCIENCES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210386733-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210196711-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2008064817-A2 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF CHIRAL EPOXIDES BY ADH REDUCTION OF KETONES SUBSTITUTED WITH ALPHA STARTING GROUPS AND CYCLISATION | ARCHIMICA GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1899313-A1 | METHOD FOR PRODUCING SINGLE ENANTIOMER EPOXIDES BY THE ADH REDUCTION OF ALPHA-LEAVING GROUP-SUBSTITUTED KETONES AND CYCLISATION | Archimica GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007113309-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
| EP-1742921-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006136289-A1 | METHOD FOR PRODUCING SINGLE ENANTIOMER EPOXIDES BY THE ADH REDUCTION OF ALPHA-LEAVING GROUP-SUBSTITUTED KETONES AND CYCLISATION | ARCHIMICA GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2005103010-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1043319-B1 | NOVEL ALKYLAMINO DERIVATIVES | MITSUBISHI CHEM CORP (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1043319-A1 | NOVEL ALKYLAMINO DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386733-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM3A | TSHR 3821/4885KDM1A 2/4885SLC6A2 4083/4885 |
| US-20210196711-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | TSHR 3736/4885KDM1A 2/4885SLC6A2 3976/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | TSHR 4247/4885KDM1A 2/4885SLC6A2 4581/4885 |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM3A | TSHR 3821/4885KDM1A 2/4885SLC6A2 4083/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | TSHR 4247/4885KDM1A 2/4885SLC6A2 4581/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | TSHR 4247/4885KDM1A 2/4885SLC6A2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.